Table 4.
Complete response to first salvage chemotherapy in 150 patients with AML in 1st relapse by duration of 1st CR and FLT3 status. Each figure indicates the number of patients achieving CR from the total number of patients with the attributes; percentages are given in parentheses. P values are for comparison between mutated and wild type patients.
| Regimen | CR Duration (1–<12 months) |
CR Duration (>12 months) |
ALL CR (>1 months) | |||
|---|---|---|---|---|---|---|
| Mutated | Wild Type |
Mutated | Wild Type |
Mutated | Wild Type |
|
| Allo transplant or HDAC-based | 2/13 (15) | 11/26 (42) | 3/6 (50) | 12/19 (63) | 5/19 (26) | 23/45 (51) |
| P = 0.09 | P=0.5 | P = 0.07 | ||||
| Other Intensive | 1/3 (33) | 3/8 (38) | - | - | 1/3 (33) | 3/8 (38) |
| P = 0.9 | P = 0.9 | |||||
| Miscellaneous, single agent or investigational | 2/10 (20) | 1/11 (9) | 0/2 | 1/5 (20) | 2/12 (17) | 2/16 (13) |
| P = 0.5 | P = 0.5 | P = 0.8 | ||||
| All | 5/26 (19) | 15/45 (33) | 3/8 (38) | 13/24 (54%) | 8/34 (24) | 28/69 (41%) |
| P = 0.2 | P = 0.4 | P = 0.09 | ||||
HDAC: high-dose ara-C; CR: complete remission